Sunday, February 22, 2026
ISSN 2765-8767
  • Survey
  • Podcast
  • Write for Us
  • My Account
  • Log In
Daily Remedy
  • Home
  • Articles
  • Podcasts
    Debunking Myths About GLP-1 Medications

    Debunking Myths About GLP-1 Medications

    February 16, 2026
    The Future of LLMs in Healthcare

    The Future of LLMs in Healthcare

    January 26, 2026
    The Future of Healthcare Consumerism

    The Future of Healthcare Consumerism

    January 22, 2026
    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    July 1, 2025

    The cost structure of hospitals nearly doubles

    July 1, 2025
    Navigating the Medical Licensing Maze

    The Fight Against Healthcare Fraud: Dr. Rafai’s Story

    April 8, 2025
  • Surveys

    Surveys

    How Confident Are You in RFK Jr.’s Health Leadership?

    How Confident Are You in RFK Jr.’s Health Leadership?

    February 16, 2026
    AI in Healthcare Decision-Making

    AI in Healthcare Decision-Making

    February 1, 2026

    Survey Results

    Can you tell when your provider does not trust you?

    Can you tell when your provider does not trust you?

    January 18, 2026
    Do you believe national polls on health issues are accurate

    National health polls: trust in healthcare system accuracy?

    May 8, 2024
    Which health policy issues matter the most to Republican voters in the primaries?

    Which health policy issues matter the most to Republican voters in the primaries?

    May 14, 2024
    How strongly do you believe that you can tell when your provider does not trust you?

    How strongly do you believe that you can tell when your provider does not trust you?

    May 7, 2024
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner
No Result
View All Result
  • Home
  • Articles
  • Podcasts
    Debunking Myths About GLP-1 Medications

    Debunking Myths About GLP-1 Medications

    February 16, 2026
    The Future of LLMs in Healthcare

    The Future of LLMs in Healthcare

    January 26, 2026
    The Future of Healthcare Consumerism

    The Future of Healthcare Consumerism

    January 22, 2026
    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    July 1, 2025

    The cost structure of hospitals nearly doubles

    July 1, 2025
    Navigating the Medical Licensing Maze

    The Fight Against Healthcare Fraud: Dr. Rafai’s Story

    April 8, 2025
  • Surveys

    Surveys

    How Confident Are You in RFK Jr.’s Health Leadership?

    How Confident Are You in RFK Jr.’s Health Leadership?

    February 16, 2026
    AI in Healthcare Decision-Making

    AI in Healthcare Decision-Making

    February 1, 2026

    Survey Results

    Can you tell when your provider does not trust you?

    Can you tell when your provider does not trust you?

    January 18, 2026
    Do you believe national polls on health issues are accurate

    National health polls: trust in healthcare system accuracy?

    May 8, 2024
    Which health policy issues matter the most to Republican voters in the primaries?

    Which health policy issues matter the most to Republican voters in the primaries?

    May 14, 2024
    How strongly do you believe that you can tell when your provider does not trust you?

    How strongly do you believe that you can tell when your provider does not trust you?

    May 7, 2024
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner
No Result
View All Result
Daily Remedy
No Result
View All Result
Home Perspectives

The Art in the Science of Virtual Care

Daily Remedy by Daily Remedy
February 13, 2022
in Perspectives
0
The Art in the Science of Virtual Care 2022.02.15

Steve Jobs was great not because of any technical skill. He was great because he could make you fall in love with technology. This is less a science and more an art. And a lesson healthcare should heed as it seeks to integrate virtual care into mainstream models of medicine.

Jobs did not integrate product features to create a smart phone. He imbued them with feelings, giving life to what would otherwise be considered as inanimate objects. He saw the world through perceptions and experiences, and wanted Apple customers to build a relationship with their phones, almost to the point of falling love, arguably the strongest of emotions.

Russian author Leo Tolstoy described this transmission of feelings as art. An analogy similar to the one Dr. William Osler used to describe his experiences with patients. Osler saw medicine as an experience developing over time, over multiple patient encounters.

The thoughts and words conveyed and exchanged during a patient encounter form a relationship, much like the relationship people have with art or an object of affection. In virtual care, that relationship includes the experience of both the care provider and the technological interface.

Therefore, for virtual care to be considered equal to traditional in-person care in terms of patient outcomes – and eventually become standard of care – the quality of communication over technological platforms must be equal to, if not better than, the communication expressed in a clinical encounter.

Clinical communication conducted virtually must embody the same ideals – compassion, sincerity, and above all, trust. In healthcare, trust is a perception that forms over time, and the quality of trust is an aggregate of all those experiences.

We remain fond of childhood toys, regardless of our age, because we associate our earliest memories with them. And the memories of those experiences evoke particular emotions of nostalgia. Trust in healthcare is built the same way. A simple handshake from a physician is as impactful as the medicines prescribed – because both are acts of trust.

In fact, no matter how far healthcare advances, it will always be defined by perceptions of trust among patients. And if virtual care seeks to be at the vanguard of healthcare advancements, then it must prioritize trust in all facets of the patient experience.

Telemedicine, the basis for most virtual care models, was never adopted as readily as during the COVID-19 pandemic. When patients could no longer see their providers, they resorted to telemedicine. We assumed it was a simple transition from an in-person encounter to a digital one – with the experiences being much the same aside from a digital interface.

But the perceptions generated during the virtual encounter were vastly different. Scores of patients rushed online to express their fears and concerns, not only to discuss their symptoms, or perceived risk of being infected with COVID-19, but also their jobs, livelihood, and other issues not traditionally associated with medical care.

But in those moments of fear, they became medical issues. And telemedicine became the platform to express this fear, cultivating a unique patient experience in the process.

Telemedicine builds patient trust as much as it treats medical conditions, like any live patient visit, but not in the same way. The trust built is distinctly different because the experiences are unique. The growth of virtual care, it then follows, depends more on the perceptions that form than by any technological feature.

Increasing the points of engagement is not the same as improving the quality of experience. The latter is perception driven and, consequently, the driver of patient trust. These perceptions, aggregated over time, will dictate how patients will adopt virtual health models.

Accordingly, we should study the unique perceptions that develop in a virtual encounter and optimize the quality of perceptions that form – and only utilize technology that prioritizes the patient experience.

ShareTweet
Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Videos

This conversation focuses on debunking myths surrounding GLP-1 medications, particularly the misinformation about their association with pancreatic cancer. The speaker emphasizes the importance of understanding clinical study designs, especially the distinction between observational studies and randomized controlled trials. The discussion highlights the need for patients to critically evaluate the sources of information regarding medication side effects and to empower themselves in their healthcare decisions.

Takeaways
GLP-1 medications are not linked to pancreatic cancer.
Peer-reviewed studies debunk misinformation about GLP-1s.
Anecdotal evidence is not reliable for general conclusions.
Observational studies have limitations in generalizability.
Understanding study design is crucial for evaluating claims.
Symptoms should be discussed in the context of clinical conditions.
Not all side effects reported are relevant to every patient.
Observational studies can provide valuable insights but are context-specific.
Patients should critically assess the relevance of studies to their own experiences.
Engagement in discussions about specific studies can enhance understanding

Chapters
00:00
Debunking GLP-1 Medication Myths
02:56
Understanding Clinical Study Designs
05:54
The Role of Observational Studies in Healthcare
Debunking Myths About GLP-1 Medications
YouTube Video DM9Do_V6_sU
Subscribe

2027 Medicare Advantage & Part D Advance Notice

Clinical Reads

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

by Daily Remedy
February 15, 2026
0

Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That is the practical question behind BIIB080, an intrathecal antisense therapy designed to reduce production of tau protein by targeting the tau gene transcript. In a phase 1b program originally designed for safety and dosing, investigators later examined cognitive, functional, and global outcomes as exploratory endpoints. The clinical question matters because current disease-modifying options primarily target amyloid, while tau pathology tracks...

Read more

Join Our Newsletter!

Twitter Updates

Tweets by TheDailyRemedy

Popular

  • The Prevention Gap in Dementia Care

    The Prevention Gap in Dementia Care

    0 shares
    Share 0 Tweet 0
  • Healthcare Natural Rights

    0 shares
    Share 0 Tweet 0
  • The Staffing Equation That Doesn’t Balance

    0 shares
    Share 0 Tweet 0
  • Healthcare in Space

    1 shares
    Share 0 Tweet 0
  • Heat Safety Tips Every Pregnant Mother Should Know

    0 shares
    Share 0 Tweet 0
  • 628 Followers

Daily Remedy

Daily Remedy offers the best in healthcare information and healthcare editorial content. We take pride in consistently delivering only the highest quality of insight and analysis to ensure our audience is well-informed about current healthcare topics - beyond the traditional headlines.

Daily Remedy website services, content, and products are for informational purposes only. We do not provide medical advice, diagnosis, or treatment. All rights reserved.

Important Links

  • Support Us
  • About Us
  • Contact us
  • Privacy Policy
  • Terms and Conditions

Join Our Newsletter!

  • Survey
  • Podcast
  • About Us
  • Contact us

© 2026 Daily Remedy

No Result
View All Result
  • Home
  • Articles
  • Podcasts
  • Surveys
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner

© 2026 Daily Remedy